Total Payments
$21,794
2024 Payments
$2,669
Companies
53
Transactions
783
Medicare Patients
13,022
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$21,637 (99.3%)
Education$143.66 (0.7%)
Consulting$12.88 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $21,637 | 766 | 99.3% |
| Education | $143.66 | 16 | 0.7% |
| Consulting Fee | $12.88 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BIOTRONIK INC. | $2,349 | 41 | $0 (2024) |
| Cardiovascular Systems Inc. | $1,798 | 17 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $1,705 | 119 | $0 (2024) |
| Amgen Inc. | $1,633 | 65 | $0 (2024) |
| Boston Scientific Corporation | $1,242 | 26 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,203 | 71 | $0 (2024) |
| Abbott Laboratories | $1,164 | 31 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $896.74 | 49 | $0 (2024) |
| Philips Electronics North America Corporation | $782.48 | 13 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $728.96 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,669 | 113 | Novartis Pharmaceuticals Corporation ($467.68) |
| 2023 | $2,664 | 88 | Philips Electronics North America Corporation ($317.99) |
| 2022 | $2,408 | 80 | BIOTRONIK INC. ($504.25) |
| 2021 | $1,896 | 98 | BIOTRONIK INC. ($183.66) |
| 2020 | $2,493 | 94 | Amgen Inc. ($322.10) |
| 2019 | $4,358 | 97 | Cardiovascular Systems Inc. ($1,039) |
| 2018 | $3,253 | 121 | Boston Scientific Corporation ($394.66) |
| 2017 | $2,053 | 92 | GE HEALTHCARE ($304.33) |
All Payment Transactions
783 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Food and Beverage | In-kind items and services | $19.46 | General |
| Category: Heart Failure | ||||||
| 12/17/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $7.13 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/10/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.12 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/03/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: DIABETES | ||||||
| 11/26/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: Cardiology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $8.83 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/22/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: Diabetes | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $6.46 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/18/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Not Applicable | ||||||
| 11/18/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $1.24 | General |
| Category: Not Applicable | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $23.08 | General |
| Category: Cardiovascular | ||||||
| 11/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $7.56 | General |
| Category: Cardiology | ||||||
| 11/08/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/06/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Diabetes | ||||||
| 11/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Cardio-renal | ||||||
| 10/30/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $7.91 | General |
| Category: Cardiology | ||||||
| 10/25/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/22/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/21/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: Not Applicable | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: Cardiology | ||||||
| 10/08/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $120.73 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/03/2024 | HEARTFLOW, INC. | FFRct (Device) | Food and Beverage | Cash or cash equivalent | $23.44 | General |
| Category: Coronary | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $10.53 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 39 | 3,479 | 5,559 | $1.5M | $641,259 |
| 2022 | 38 | 3,326 | 5,489 | $1.5M | $640,023 |
| 2021 | 37 | 3,174 | 5,581 | $1.7M | $693,384 |
| 2020 | 37 | 3,043 | 4,838 | $1.4M | $569,533 |
Total Patients
13,022
Total Services
21,467
Medicare Billing
$2.5M
Procedure Codes
155
All Medicare Procedures & Services
155 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93229 | Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | Office | 2023 | 164 | 171 | $256,500 | $161,048 | 62.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 525 | 899 | $179,800 | $102,212 | 56.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 284 | 294 | $286,650 | $56,369 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 223 | 344 | $86,000 | $54,323 | 63.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 94 | 95 | $137,750 | $44,744 | 32.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 105 | 270 | $43,200 | $29,619 | 68.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 100 | 100 | $40,000 | $19,549 | 48.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 104 | 108 | $32,400 | $17,186 | 53.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 67 | 68 | $56,100 | $16,151 | 28.8% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 94 | 190 | $33,250 | $14,739 | 44.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 53 | 53 | $22,525 | $10,881 | 48.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 47 | 328 | $14,760 | $10,572 | 71.6% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 43 | 44 | $39,600 | $8,329 | 21.0% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 47 | 188 | $14,100 | $7,925 | 56.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 22 | 42 | $16,170 | $7,897 | 48.8% |
| 92941 | Removal of plaque and blood clot, insertion of stent and/or balloon dilation of single vessel | Facility | 2023 | 14 | 14 | $28,000 | $7,844 | 28.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 113 | 120 | $27,000 | $7,565 | 28.0% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 101 | 104 | $33,800 | $6,623 | 19.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 337 | 433 | $43,300 | $5,982 | 13.8% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 52 | 53 | $7,950 | $4,322 | 54.4% |
| 93228 | Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | Office | 2023 | 165 | 173 | $6,920 | $4,036 | 58.3% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 32 | 172 | $8,600 | $4,019 | 46.7% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Office | 2023 | 13 | 13 | $7,475 | $3,735 | 50.0% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 18 | 158 | $10,270 | $3,597 | 35.0% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 12 | 14 | $6,650 | $3,427 | 51.5% |
About Dr. John Kao, M.D
Dr. John Kao, M.D is a Cardiovascular Disease healthcare provider based in San Jose, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497737191.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Kao, M.D has received a total of $21,794 in payments from pharmaceutical and medical device companies, with $2,669 received in 2024. These payments were reported across 783 transactions from 53 companies. The most common payment nature is "Food and Beverage" ($21,637).
As a Medicare-enrolled provider, Kao has provided services to 13,022 Medicare beneficiaries, totaling 21,467 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 155 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Interventional Cardiology
- Location San Jose, CA
- Active Since 11/17/2005
- Last Updated 06/27/2014
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1497737191
Products in Payments
- Repatha (Biological) $1,559
- ELIQUIS (Drug) $1,230
- XARELTO (Drug) $1,203
- ENTRESTO (Drug) $1,117
- Coronary Orbital Atherectomy System (Device) $705.20
- LEQVIO (Drug) $588.00
- VERQUVO (Drug) $484.79
- BRILINTA (Drug) $468.00
- Vascepa (Drug) $443.85
- NEXLETOL (Drug) $379.73
- Edora 8 DR-T (Device) $332.82
- Arcalyst (Drug) $332.10
- CardioMEMS HF System (Device) $325.97
- Carnation Ambulatory Monitor (Device) $311.09
- BIOMONITOR (Device) $281.65
- OPSUMIT (Drug) $276.24
- Impella (Device) $272.83
- Letairis (Drug) $238.88
- KENGREAL (Drug) $233.11
- Lutonix Drug Coated Balloon (Device) $224.06
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in San Jose
Dr. Mohammed Qayyum, Md, MD
Cardiovascular Disease — Payments: $195,680
Cardiovascular Disease $195,680
Andrew Kwa, M.d, M.D
Cardiovascular Disease — Payments: $137,381
Cardiovascular Disease $137,381
Matthew Levy, M.d, M.D
Cardiovascular Disease — Payments: $66,907
Cardiovascular Disease $66,907
John Lien, Md, MD
Cardiovascular Disease — Payments: $42,400
Cardiovascular Disease $42,400
Dr. Thirupathi Reddy, Md, MD
Cardiovascular Disease — Payments: $41,933
Cardiovascular Disease $41,933
Mehrdad Rezaee, Md Phd, MD PHD
Cardiovascular Disease — Payments: $20,025
Cardiovascular Disease $20,025